Pfizer is one step closer to another $1 billion-plus in sales for its Prevnar 13 franchise. Data from a huge new study showed that Prevnar worked at preventing pneumonia in patients 65 or older, which puts the vaccine in line for stepped-up use.
The New York-based drugmaker is keeping the data under wraps until next month but has revealed the headline results. Primary and secondary objectives were all met.
Pfizer CEO Ian Read has become the first pharma executive to contribute an article to LinkedIn's publishing platform.
According to the latest survey from PatientView, in the healthcare industry, multinational pharma companies rank next to last, reputation-wise. Biotech companies come in just above that. Since 2011, pharma's reputation, already not so hot, has slipped even further.
Anyone reading the news this week knows what a stray remark from a CEO can do. But pharma executives don't have to mention "distressed babies"--or something equally telegenic--to get themselves in trouble.
The antitrust crackdown in pharma has moved to Australia. Once again, Pfizer finds itself in the middle of a legal fight over its efforts to hang onto Lipitor sales after the drug went off patent and faced competition from cheaper generics.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug...
For an undisclosed amount, Pfizer signed a deal to use the San Diego company's TriGrid intramuscular electroporation system, which creates temporary pores in cell membranes, allowing vaccines to become more thoroughly entrenched. Pfizer is interested in making the technology a part of its preclinical cancer vaccine-based immunotherapy research program, according to a release from Ichor.
Ichor Medical Systems said it will develop electroporation devices for use in Pfizer's preclinical cancer vaccine research efforts.
At Merck, the already giant-sized hope that its cancer immunotherapy program for the PD-1 drug MK-3475 represents just swelled significantly in importance. Just ahead of its 2013 earnings report Wednesday, the pharma giant announced plans to tie up with a trio of major league biopharma partners to launch a whole new slate of combination studies that could significantly extend its reach in the oncology market.